Prior AE s are those occurring after subject sign off the informed consent and before the administration of the first dose of study treatment. Drug -related ness to the study drugs is captured in five categories as follows: • Definitely related (The AE is c learly related to the inve stigational agent) Sponsor: Ludwig Institute for Cancer Research. Protocol Number: LUD2014- 012-VAC. CONFIDENTIAL SAP Version: 3.0 Effective Date: 09DEC2020 Page 13 of 27 • Probably rel ated (The AE is likely r elated to the inve stigational agent) • Possibly related (The AE may be r elated to the inve stigational agent ) • Unlikely related (T he AE is doubtf ully r elated to the investi gational agent) • Unrelated (The AE is clearly not r elated to the inve stigational TEAEs are considered as related to the study drug if enterd as definitely , probably or possibly related to study drug as assessed by the Investigator. If a subject has multiple occurre nces of the same system organ class (SOC) or preferred term, then only the most sever e event will be summar ized in the tables for that SO C and pre ferred term. 9.1.1 Treatment -Emergent Adverse Events Treatment -emergent adverse events (TEAEs) are defined as any AEs that started aft er dosi ng or wors ened in seve rity after dosi ng. An overall AE summary for number of subjects will be presented for the following categories: • Any Adverse Event • Any TEAE • Any Deaths within the AE reporting period • Any study drug- related adverse event (TRAE) (i.e., related to durval umab, tremelimumab and/or vaccine) o Any durvalumab related TR AE o Any tremelimumab related T RAE o Any vaccine related T RAE • Any TEAE ≥ CTCAE Grade 3 • Any TR AE ≥ CTCAE Grade 3 • Any treatment -emergent Serious AEs (SAE s) • Any Serious TRAEs • Any TEAE leading to treatment (durval umab, tremelimumab, and/or vaccine) discontinuation o Related to durvalumab o Related to tremelimumab o Related to vaccine Sponsor: Ludwig Institute for Cancer Research. Protocol Number: LUD2014- 012-VAC.